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LipophilicityAbstract Gemiﬂoxacin, a novel, 4th generation ﬂuoroquinolone derivative, was labeled with99mTc;
its freeze dried kits were prepared and used for infection imaging. Kits showed great stability with
higher labeling efﬁciency. Kits were synthesized through a simple method; developed at room tem-
perature without HCl and heating with low colloidal content. Reaction conditions were optimized
in order to get maximum radiochemical purity. Highest labeling efﬁciency (99 ± 0.05)% was
achieved when 1.0 mg gemiﬂoxacin was labeled with 10 mCi sodium pertechnetate in the presence
of 50 lg SnCl2 and 300 lg D-penicillamine at room temperature. Radiolabeled antibiotic kits were
preclinically assessed such as in-vitro stability, lipophilicity, protein binding, in-vitro binding with
bacterial strains and pharmacokinetic investigations in animals. Kits were found highly stable for
6 h both at room temperature and at 37 C in serum. Biodistribution showed excellent uptake of
activity at infection site (in Pseudomonas aeruginosa, Salmonella typhi and Klebsiella pneumoniae).
Biodistribution data showed that 99mTc-gemiﬂoxacin has the potential and may be used for infec-
tion imaging.
 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nuclear Medicine Imaging Technology (NMIT) provides a
key role in diagnosis of infection foci and its distinction is rec-
ognized due to accuracy and speciﬁcity. Fluoroquinolones are
the antibiotics that speciﬁcally bind with bacteria DNA gyrase
and stop its proliferation. Ciproﬂoxacin, a ﬂuoroquinolone
derivative is considered as a speciﬁc and sensitive tool foras aerug-
2 S. Shahzad et al.discrimination among sterile inﬂammation and bacterial infec-
tion (Chattopadhyay et al., 2010; Dumarey et al., 2002;
Gemmel et al., 2004; IAEA, 2008). It has a lot of advantages
over the radiolabeled leukocytes for infection diagnosis such
as better bacterial binding and convenient preparation.
(Vinjamuri et al., 1996; Britton et al., 1997; Hall et al., 1998;
Larikka et al., 2002a,b). Conversely, the literature shows cer-
tain problems in its synthesis (Oh et al., 2002; Siaens et al.,
2004) that includes its low radiochemical yield, signiﬁcant
amount of colloid (99mTcO2). Furthermore, heating and addi-
tional puriﬁcation is required in preparation of 99mTc-
ciproﬂoxacin (Britton et al., 1997). For routine clinical analysis
these procedures are hectic and time consuming. Gemiﬂoxacin,
ﬂuoroquinolone derivative, a novel antibiotic, structure is
given in Fig. 1(a); is active against many strains of gram
positive and gram negative bacteria e. g multi-drug resis-
tant Streptococcus pneumoniae (MDRSP), Haemophilus
parainfluenzae, Haemophilus influenzae,Moraxella catarrhalis,
Klebsiella pneumoniae, Klebsiella oxytoca, Acinetobacter
lwoffii, Proteus vulgaris. Legionella pneumophila and other
micro-organisms e.g. Chlamydia pneumoniae,Mycoplasma
pneumoniae. It is found more efﬁcient against many bacterial
strains than gatiﬂoxacin, moxiﬂoxacin, ciproﬂoxacin and levo-
ﬂoxacin (Blondeau and Tillotson, 2007; Al-Hadiya et al.,
2010). Literature revealed that gemiﬂoxacin kits were prepared
and its biodistribution was investigated in Streptococcus
pneumonia (Shah and Khan, 2011). Data showed that labeling
of 99mTc with gemiﬂoxacin as well as it’s in- vivo study is
preliminary. In order to explore more efﬁcient conditions for
its radiolabeling, extensive research is required. Some
organized experimentation is necessary in order to explore
complete outline of pharmacokinetics and efﬁcacy for
99mTc-gemiﬂoxacin against a wide variety bacteria. The
objective of present study was to explore a simple and robustFigure 1 (a) Structure of gemiﬂoxacin. (b) Structure of 99mTc-
gemiﬂxacin.
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with 99mTc having low colloidal (stable in serum), free from
HCl, heating, and carried out at room temperature. This
labeled kit formulation was optimized for preclinical assess-
ments with respect to radiochemical purity, in vitro and
in vivo studies to sketch the whole proﬁle of the pharmacoki-
netics of 99mTc-gemiﬂoxacin. Kits were then freeze dried after
18 h of lyophilization. The freeze dried single vial kits were
developed into 99mTc-gemiﬂoxacin, and successfully utilized
to recognize infections in Salmonella typhi, Pseudomonas
aeruginosa and Klebsiella pneumoniae infected rabbits.2. Experimental
2.1. Materials and methods
Octanol (Sigma Aldrich, USA), D-Mannitol (Sigma Aldrich,
USA), Sodium pyrophosphate (RDH, Germany), Acetone
(Merck, Germany), D-Penicillamine (Sigma Aldrich, USA),
Trichloro acetic acid (Fisher scientiﬁc, UK), Stannous chloride
(Sigma Aldrich, USA), 99Mo/99mTc generator was used to get
99mTc, PINSTECH, Islamabad, Pakistan. Gemiﬂoxacin (Java
pharmaceutical, Lahore, Pakistan), Saline (Otsuka, Pakistan),
0.22 lm ﬁlter (MS Nylon Membrane Filters, USA) were
used. Rabbits were purchased from Tollinton market, Lahore.
All chemicals used were of analytical grade and used without
further puriﬁcation.
2.2. Gemifloxacin kit preparation
The best conditions for radiolabeling of gemiﬂoxacin with
technetium were calculated through optimization studies. It
includes varying gemiﬂoxacin concentration, stannous chloride
concentration, pH, and reaction time. Tests were carried out in
triplicates (n= 3). Gemiﬂoxacin kits with maximum labeling
efﬁciency (99 ± 0.05)% were obtained when 1 mg gemi-
ﬂoxacin, 300 lg D-penicillamine, 50 lg stannous chloride
and 0.2 g d-mannitol were dissolved by simple stirring in
1 ml of distilled water at pH 5.5 (1 N NaOH/1 N HCl). Kits
prepared were ﬁltered by 0.22 lm ﬁlter (MS Nylon Mem-
brane Filters, USA) and lyophilised for 18 h. These freeze
dried kits were stored at 4 C. This whole process of kit formu-
lation was carried out under sterile conditions at room
temperature.
2.3. Radiolabeling
Sodium pertechnetate (10 mCi) was freshly eluted, drawn up
by an in-house packgen 99mTc generator, was added to freeze
dried kits and incubated for 10–15 min at room temperature.
2.4. Radiochemical analysis
Radiochemical purity was tested by PC and ITLC and RP-
HPLC. In paper chromatography, whatman No. 3 paper and
acetone was used. It was carried out to check the percentage
of unbound pertechnetate (99mTcO4
). In ITLC, saline was
used as solvent. It was used to investigate the amount of
hydrolyzed/reduced technetium (99mTcO2). In ITLC,
99mTc-
gemiﬂoxacin travel with solvent front and hydrolyzed/reducedeeze dried kits and their biodistribution in Salmonella typhi, Pseudomonas aerug-
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Synthesis and biodistribution of 99mTc-gemiﬂoxacin freeze dried kits 399mTcO2 hold at origin. In HPLC analysis of
99mTc-
gemiﬂoxacin a volume of 10 lL of the solution was injected.
Nucleosil C-18 column (100 A˚, 5 lm, 250  4 mm) was used
for analytical separation as stationary phase while solvent A
(0.1% TFA in H2O), solvent B (Acetonitrile) was used as
mobile phase with ﬂow rate of 0.5 mL/min. The summary of
gradient program is given in Table 1. Radio-HPLC was used
for the detection of 99mTc-complexes. NaI (Tl) scintillation
detector was used for radioactivity study and it is separated
by a Teﬂon tube from UV detector.
2.5. In vitro stability tests
In vitro stability study of 99mTc-gemiﬂoxacin was performed to
analyse any degradation of the labeled complex at room tem-
perature and to ﬁnd out suitable time of injecting the complex
in order to avoid undesired products formation (radiolysis of
the labeled complex) which may accumulate in non target
organs. In vitro stability of 99mTc-gemoﬂoxacin was performed
in blood serum to detect any degradation of the complex by
blood enzymes. For this, 5 ml blood was centrifuged for
10 min at 3000 rpm. Blood cells were separated from serum,
99mTc-gemiﬂocacin kit was added into it, and incubated at
37 C. Radiochemical purity of the incubated kit was analyzed
from 1 h–6 h, in continuous intervals by PC and ITLC. The
results are reported in Table 3 (n= 3).
2.6. Partition coefficient (Log P)
Partition coefﬁcient was calculated in octanol/saline as organic
and inorganic layers. Counts were calculated in 100 lL of both
the organic and inorganic layers by well-shaped gamma ray
counter. Partition coefﬁcient values were calculated by mean
(n= 3).
Log P Value : Log ð% in octanol =% in salineÞ2.7. Serum protein binding
Serum protein binding was calculated by adding radiolabeled
kit in fresh human blood, incubating for 1 h (25 C), incubat-
ing for 10 min at 37 C, and centrifuged at 3000 rpm. Trichloro
acetic acid (TCA10%), in equal volume as serum, added, stir-
red well, and centrifuged at 3000 rpm (10 min). Both super-
natant and residue were counted for radioactivity (n= 3).
2.8. In vitro binding assay of 99mTc-gemifloxacin with bacteria
In vitro binding efﬁciency of the complex was investigated in
Pseudomonas aeruginosa, Salmonella typhi, and Klebsiella
pneumoniae via cylinder plate method for microbiologicalTable 1 Eluent gradient program.
Time Solvent A (%) Solvent B (%)
0 min 95 5
5 min 95 5
25 min 0 100
30 min 0 100
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(USP-27, 2004).
% Binding to Bacteria ¼ Counts in Pellet
=ðCounts in Supernatant
þ Counts in PelletÞ  1002.9. Biodistribution
For biodistribution, in normal rabbit, 99mTc-gemiﬂoxacin
(1 mL) was injected through iliac vein of the rabbit prior val-
ium anesthesia (2.0 mg/mL). Scintigraphic images were taken
to locate the path of injected medicine. Biodistribution in
infected rabbits was observed, by injecting 1 mL suspension
(3  108 cfu/mL) of P. aeruginosa, S. typhi and K. pneumoniae
separately in thigh muscles of rabbits. When infection and the
swelling started in all rabbits, the radiolabeled complex
(1 mL = 2.5 mCi) was injected in the iliac veins of all the rab-
bits separately after valium anesthesia (1 mL). Scintigraphic
images were taken at (1–4 h) and 24 h post injection by Inﬁnia
Dual Head Gamma Camera.
3. Results and discussion
In the structure of gemiﬂoxacin Fig. 1(a), electron donating
atoms are present e.g. oxygen, nitrogen. These atoms interact
with 99mTc to form a complex, SnCl2 and D-pencillamin help
in this complex formation. Though exact structure of 99mTc-
gemiﬂoxacin is not known, rather a proposed structure of
complex is provided in Fig. 1(b).
It was revealed that after optimization of labeling condi-
tions, highest labeling efﬁciency was obtained. Complex for-
mation is favorable towards acidic pH but shifting towards
basic pH, it was decreased. Maximum labeling yield was (99
± 0.05)%. Following parameters were assessed for optimiza-
tion studies.
3.1. Reducing agent (SnCl2) effect
It is most common reducing agent used for the reduction of
pertechnetate that favors its complex formation through chela-
tion. Amount of reducing agent has quite strong effect on the
labeling yield. When its amount was increased, labeling yield
was also observed to increase and subsequent decrease in the
amount of free pertechnetate and colloidal form. At 50 lg,
labeling efﬁciency was found to increase (99 ± 0.05)%. While
increasing the amount of stannous chloride above 50 lg, col-
loidal amount started increasing and reached to a large value
when amount of SnCl2 was 300 lg with corresponding
decrease in labeling efﬁciency.
The results are summarized in Table 2.
3.2. Gemifloxacin quantity
Gemiﬂoxacin amount was varied between 0.5 to 3 mg to opti-
mize for minimum quantity of gemiﬂoxacin that can give the
maximum labeling. When gemiﬂoxacin amount was 0.5 mg
labeling efﬁciency was 81.75% and at 1 mg labeling efﬁciency
was reached to its maximum labeling efﬁciency (99 ± 0.05)%.
Above 1 mg the labeling efﬁciency remained stable and noeeze dried kits and their biodistribution in Salmonella typhi, Pseudomonas aerug-
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Table 2 Effect of pH and SnCl2 (reducing agent) on labeling efﬁciency.
pH Concentration of SnCl2 (lg)
3 4 5 6 7 25 50 100 200 300
Labelling eﬃciency (%) 89.01 92.7 99.01 94.95 47.7 57.03 99.05 98.60 98.00 76.30
Free 99mTcO4
 9.90 4.7 0.63 4.00 50.3 40.6 0.40 0.40 0.30 0.31
Colloids/hydrolysed (99mTcO2) 1.09 2.6 0.36 1.00 2.76 2.7 0.10 1.00 1.70 21.39
Figure 2 Effect of gemiﬂoxacin concentration on labeling
efﬁciency. Figure 3 Effect of incubation time on labeling efﬁciency.
Table 3 In vitro stability of 99mTc-gemiﬂoxacin.
Stability study at room temperature In vitro stability study in serum at 37 C
Time (h) Time (h)
1 2 3 4 5 6 1 2 3 4 5 6
Labelling eﬃciency (%) 99.39 99.00 98.99 98.90 98.72 98.60 99.24 99.10 99.04 98.70 98.47 98.40
Free 99mTcO4
 0.41 0.50 0.51 0.55 0.78 0.70 0.50 0.45 0.56 0.70 0.83 0.84
Colloids/hydrolysed (99mTcO2) 0.30 0.50 0.50 0.55 0.50 0.70 0.26 0.45 0.50 0.60 0.70 0.76
4 S. Shahzad et al.major impact was observed on labeling efﬁciency, free pertech-
netate and colloidal forms (Fig. 2).
3.3. pH effect
pH has strong effect on labeling efﬁciency. Labeling efﬁciency
was low at low pH. By increasing pH, labeling efﬁciency was
also increased up till pH 5.5. After pH 5.5, labeling efﬁciency
decreased with subsequent increase in amount of reduced/
hydrolyzed (99mTcO2) and free
99mTcO4
 (Table 2).
3.4. Effect of incubation time
99mTc-gemiﬂoxacin complex was developed in a small time.
After 5 min, labeling efﬁciency was (94 ± 0.12)%. After
15 min, highest labeling efﬁciency was observed and became
steady after it (Fig. 3).Please cite this article in press as: Shahzad, S. et al., Synthesis of 99mTc-gemifloxacin fr
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After optimization studies highest labeling efﬁciency (99
± 0.05)% was achieved using 1.0 mg gemiﬂoxacin, 50 lg stan-
nous chloride, 300 lg D-penicillamine, 0.2 g D-mannitol, and
10 mCi sodium pertechnetate at pH 5.5. When complex was
characterized by ITLC, minor activity remained at origin that
is reduced 99mTc, while major part of activity moved upward
that represents 99mTc-gemiﬂoxacin. In PC major activity
remained at the origin that represents the 99mTc-gemiﬂoxacin
and minor activity was travelled that is free 99mTcO4. In
HPLC studies of 99mTc-gemiﬂoxacin a single complex was
detected with retention time 11.60 min (Fig. 4) by radioactive
detector which is similar to as previously reported in the liter-
ature (Shah and Khan, 2011). While the retention time of the
pure gemiﬂoxacin is 8.0 min under the same chromatographic
conditions.eeze dried kits and their biodistribution in Salmonella typhi, Pseudomonas aerug-
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Figure 4 HPLC chromatogram; showing three peaks, one main
peak at 11.60 due to 99mTc-gemiﬂoxacin with radiochemical purity
(99 ± 0.05)% and two small peaks showing free and Colloidal
forms of technetium.
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Labeling efﬁciency, free 99mTcO4
 and reduced/hydrolyzed
99mTcO2 remained constant with some insigniﬁcant changes
for 6 h both at room temperature and in freshly prepared
blood serum at 37 C (Table 3).
3.7. Partition co-efficient
Partition co-efﬁcient study showed that the complex has
hydrophilic behavior. LogP value is 3.01, suggesting low
lipophilicity of the complex.
Log P value ¼ Log ð0:09=99:91Þ ¼ 3:01Table 4 Bio-distribution of 99mTc-gemiﬂoxacin in Salmonella typhi
Organ 1 h 2 h
Thigh (T) 5.33 ± 0.23 6.06 ±
Thigh (NT) 2.58 ± 0.20 1.49 ±
Kidneys (RT) 2.39 ± 0.20 3.27 ±
Kidneys (LT) 0.26 ± 0.08 2.99 ±
Liver 3.26 ± 0.11 2.97 ±
Urinary bladder 31.07 ± 0.45 46.77 ±
(a) Ant View        (b) Ant.View
Figure 5 Scintigrams showing radioactivity uptake in Salmonella ty
Views.
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The complex showed a moderate binding with serum protein
and found 55.8% in bound form (with protein) and 44.2%
in unbound form.
% of supernatant ¼ Counts in supern:=ðCounts in supern:
þ Counts in residueÞ  100 ¼ 44:2%
% of residue ¼ Counts in residue=ðCounts in supernatant
þ Counts in residueÞ  100 ¼ 55:8%3.9. Biodistribution study in normal and infected rabbits
Biodistribution in normal rabbit showed that kidneys and
urinary bladder is the main route of excretion of medicine.
In vivo study of 99mTc-gemiﬂoxacin in infected rabbits was
investigated in P. aeruginosa, S. typhi and K. pneumoniae.
Radioactivity was counted immediately after injecting the
complex in thigh muscle. At the start maximum uptake was
found in the liver, kidneys and bladder but with the passage
of time these organs showed less activity signifying that its
wash out is time dependent. Uptake of activity in both legs
muscles shows a sharp difference after 4 h. Activity uptake in
P. aeruginosa was 5.84 ± 0.09%ID/g and in S. typhi was
6.06 ± 0.26%ID/g and in K. pneumoniae was 6.55 ± 1.1%
ID/g at 2 h post injection; these results are better than
99mTc-ciproﬂoxacin uptake value at 2 h post injection i.e. starts
excreting from infection after 1 h (Tables 4, 5 and 6). Activity
was not seen in stomach, suggesting stability of kits in vivo
conditions i.e. no colloidal (disintegration of the kit) was
formed which was the issue in labeling of quinolones in early
studies (Sarda et al., 2003; Britton et al., 1997). After 24 h post(%ID/g ± SD, n= 3).
3 h 4 h
0.26 5.03 ± 0.27 4.24 ± 0.22
0.17 0.89 ± 0.08 0.53 ± 0.07
0.12 3.06 ± 0.12 1.63 ± 0.25
0.18 1.55 ± 0.16 1.12 ± 0.23
0.13 2.19 ± 0.14 0.81 ± 0.15
0.42 55.23 ± 0.34 61.78 ± 0.33
(c) Post View (d) Post view
phi at 1 h (a), 2 h (b), 4 h (c) and 24 h (d) Anterior and Posterior
eeze dried kits and their biodistribution in Salmonella typhi, Pseudomonas aerug-
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Table 5 Bio-distribution of 99mTc-gemiﬂoxacin in Klebsiella pneumoniae (%ID/g ± SD, n= 3).
Organ 1 h 2 h 3 h 4 h
Thigh (T) 4.53 ± 0.56 6.55 ± 1.1 5.25 ± 1.0 4.88 ± 0.52
Thigh (NT) 2.84 ± 0.70 1.97 ± 0.41 0.84 ± 0.81 0.55 ± 0.76
Kidneys (RT) 2.89 ± 0.91 1.75 ± 0.62 1.45 ± 0.72 0.67 ± 0.66
Kidneys (LT) 2.67 ± 1.21 1.96 ± 0.20 0.98 ± 0.52 0.94 ± 0.70
Spleen 2.70 ± 1.1 1.65 ± 0.91 0.47 ± 0.41 0.33 ± 0.31
Urinary bladder 50.30 ± 1.1 72.94 ± 1.3 63.60 ± 1.5 50.95 ± 1.2
Table 6 Biodsitribution of 99mTc-gemiﬂoxacin in Pseudomonas aeruginosa (%ID/g ± SD, n= 3).
Organ 1 h 2 h 3 h 4 h
Thigh (Target) 3.92 ± 0.08 5.84 ± 0.09 5.46 ± 0.07 4.79 ± 0.06
Thigh (NT) 2.44 ± 0.08 1.38 ± 0.01 0.53 ± 0.05 0.29 ± 0.02
Kidneys (RT) 2.83 ± 1.10 2.52 ± 1.20 1.58 ± 1.30 0.63 ± 1.23
Kidneys (LT) 2.16 ± 1.41 1.60 ± 1.23 1.40 ± 1.20 1.04 ± 1.4
Liver 2.27 ± 1.21 1.75 ± 1.21 1.66 ± 1.29 1.07 ± 1.26
Urinary bladder 57.21 ± 1.2 65.97 ± 1.22 72.97 ± 1.25 6.92 ± 1.27
Figure 6 Scintigrams showing uptake of 99mTc-gemiﬂoxacin in Klebsiella pneumoniae at 1 h (e) Anterior View, 2 h (f) Posterior View and
4 h (g) Anterior View.
Figure 7 Scintigrams showing uptake of 99mTc-gemiﬂoxacin
complex in Ps. aeruginosa infection in leg muscle of rabbit at 1 h
(h) Anterior View, 4 h (i) Posterior View.
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good binding of 99mTc-gemiﬂoxacin with bacteria (Fig. 5). S.
pneumonia infected rats were used in past for in vivo
study of labeled gemiﬂoxacin; we have utilized rabbits. To best
of our information no previous study was reported on
biodistribution of 99mTc-gemiﬂoxacin in Pseudomonas
aeruginosa, Salmonella typhi and Klebsiella pneumonia abscess.
Scintigrams of this study are presented in Figs. 5, 6 and 7.
4. Conclusion
99mTc-gemiﬂoxacin freeze dried kits were developed with high-
est labeling efﬁciency in current exploration via a simple,
rapid, and robust method. Kits were highly stable and secure
to use due to low colloidal. Both in vitro and in vivo studies
showed encouraging results. The kits can be used in clinical
examinations for the diagnosis of respiratory tract bacterial
infections such as lungs, sinus bone, and air ways as well as
ear and eye infections.eeze dried kits and their biodistribution in Salmonella typhi, Pseudomonas aerug-
i.org/10.1016/j.arabjc.2015.10.002
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